Baricitinib: key results of long-term use in rheumatoid arthritis
This review presents the latest data on the long-term use of the selective Janus kinase inhibitor (JAKi) baricitinib (BARI) in patients with rheumatoid arthritis (RA) in real-world clinical practice. The results of long-term use (up to 9.5 years) of BARI in RA suggest that its efficacy is comparable...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2024-08-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1628 |